Oversight and Monitoring of Investigational Medical Product Trials in the UK

1. Background

Oversight and monitoring activities encompass a range of processes to ensure compliance with legislation, protection of trial participants' rights, safety, and wellbeing, and reliability of trial results. These activities include committees for managing trials or reviewing safety data, central review of clinical trial data, documents and reports, feedback from investigator questionnaires, data management processes, statistical review, pharmacovigilance signal detection, and regular review meetings (e.g., sponsor with Contract Research Organisation (CRO) or Chief Investigator). Audits and site visits by trial monitors and auditors are considered part of oversight. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Oversight is crucial when sponsors delegate functions to other parties, such as Chief Investigators or external CROs. Sponsors must verify appropriate conduct through project management and governance, including approval of protocols, case report forms (CRFs), standard operating procedures (SOPs), analysis plans, and data management plans. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Monitoring assures compliance with legislation and trial protocols/procedures, providing opportunities for process improvement. Traditionally, monitoring focused on on-site visits for quality control, especially by commercial sponsors per ICH GCP guidance. Non-commercial trials often use centralized approaches with less on-site reliance. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Audits are sample-based, occurring during or after trials, or for cause based on monitoring issues. Auditors assess monitoring effectiveness and compliance with protocols, monitoring plans, and SOPs. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2. Procedures

2.1 Risk-Based Monitoring Strategy

A proportionate, risk-based approach is recommended, based on trial risk assessments identifying critical activities/data impacting participant safety, trial results reliability, and compliance. This aligns with ICH GCP, requiring sponsors to determine monitoring extent and nature. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Factors influencing the strategy include: Trial categorisation (A, B, or C per MRC/DHSC/MHRA risk-adapted approach). Protocol complexity (e.g., multiple objectives, extensive data). Novelty (e.g., new methods/equipment). Endpoint measurements (e.g., electronic collection/transfer). Trial size (multicentre, multinational, participant numbers, data volume). Vulnerable participants (e.g., consent via parents/carers). Investigator site type and staff experience. Electronic data capture (e.g., eCRF audit trails). Use of commercial/academic CROs and their assessment. CRF complexity and usability. Training needs for monitoring staff, investigators, and teams. Effectiveness of central monitoring (e.g., limited in single-site trials). https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.2 Documentation

Risk assessments document oversight/monitoring actions to mitigate risks, often in protocols, SOPs, monitoring plans, committee charters, data management plans, validation plans, medical monitoring plans, and pharmacovigilance plans. Clarity on linkages and an overriding document are recommended, especially for delegated functions (e.g., to CROs). https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities For multiple trials, procedures control content, versioning, and maintenance. Templates ensure comprehensive content, including: Links to risk assessments. Oversight of investigators/vendors. Monitoring types (central, remote, on-site). Standards/SOPs/templates. Cross-references to related documents. Site assessment/initiation procedures. Training for staff. Monitoring frequency. Communication with vendors/sites. Site capacity per monitor. Departments visited. Data reviewed (% SDV, critical data). Data validation specifications. Collection/transfer methods. System validation. Unblinded monitors/reviewers. Investigator availability. Non-compliance recording/resolution. Site file oversight. Escalation processes (e.g., triggers for on-site visits). Supplies management (IMP, temperature excursions). SAE reporting. AE/SAE review, signal detection. Query management. Report types, formats, responsibilities, timelines. Committee roles (adjudication, data monitoring). Interim analysis processes. Trial Master File management. Regulatory/ethics approval maintenance. Contract/insurance review. Audit plans. Randomisation checks. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Cross-functional reviews ensure consistency. No additional documentation submission to MHRA or REC is required for approval; protocols must include monitoring policy per GCP principles. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities For multi-country trials, global documentation suffices, with country-specific procedures if needed. Site-specific actions may apply. Strategies must be followed, with deviations documented, justified, and impact assessed. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Evidence of activities (e.g., reports, metrics) must be retained, including central/statistical monitoring documentation. Non-compliance must be addressed timely, with escalation documented. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.3 Adaptation of Strategies

Strategies adapt based on categorisation (A/B/C) and ongoing risk assessments, incorporating flexibility (e.g., reduced intensity with compliance). Documents should allow for adaptations like increased monitoring for new sites or triggered visits from central monitoring concerns. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities Escalation processes and resources are required. Decisions may delegate to monitors, overseen by project managers/Chief Investigators/steering groups. Rationale for changes documented; amendments if beyond flexibility scope. Review strategies with protocol/risk assessment/investigator brochure amendments or significant events. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities For low-risk Type A trials, oversight may reduce (e.g., initiation oversight, questionnaires, audits), but some activity needed; no monitoring rare, requiring contingency plans. Small, investigator-led trials on licensed IMPs for scientific investigation may need minimal/no on-site/central monitoring if risk-assessed. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.4 Intensity and Focus

Focus varies by trial type: Type A (IMP per clinical practice) with vulnerable/emergency research: 100% SDV of consent; limited/no IMP accountability monitoring. Pharmacokinetic trials: Detailed processing review for protocol compliance. Type C (unlicensed IMP): Detailed accountability monitoring; increased for storage needs (e.g., remote data verification). https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.5 Oversight Committees

Committees mitigate risks: Trial Management Committee (TMC) for operational oversight; Trial Steering Committee (TSC) for strategic, with independents. Functions: Ensure compliance, resource, progress; review strategies; decide escalations/adaptations. DMC for safety/efficacy reviews, un-blinded data. Not needed for small single-site trials under direct control. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.6 On-Site Monitoring Visits

No legislative requirement for regular visits; MHRA accepts central monitoring per ICH GCP revisions, if risk-justified as exceptional. Site assessment: Documented (e.g., feasibility via review/telephone/video); may not require visit if site known/recent reports suffice. Risk assessment considers selection. Initiation: Training documented (e.g., visits, central/web-based, packages/checklists). Evidence of effectiveness retained; addresses new staff. Ongoing: Benefits include SDV, team interaction, facility review, IMP checks, file/archiving assessment. Frequency risk-based (e.g., once post-initiation); triggered if central monitoring issues. Close-out: Ensure filing, IMP return/destruction, data collection, no queries. May be remote; risk assessment considers needs, retention (5+ years). https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.7 Central Monitoring

Involves clinical operations, data management, statistics, etc. SOPs for multiple trials. Document communications (calls/emails/letters). Documents received: Consent/eligibility, status reports, questionnaires, pharmacy records. Maintain blinding; retain evidence, not copies. Consent for data sharing; GDPR compliance. CRF submission (eCRF/paper); retain interrogation evidence (timeliness, audit trails, queries, SAEs, reconciliations). Data validation focused on critical data; document checks/inconsistencies. Issue/query processes with escalation; retain evidence. Investigators retain source documents; additional site activities aid GCP compliance. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.8 Statistical Monitoring

Aspect of central monitoring: Analyze accumulating data (e.g., SAEs, completion times, queries) statistically for outliers/patterns. Uses metrics like recruitment rates, screen failures, query resolution, SAEs, withdrawals, non-compliances, audit trails. Triggers targeted monitoring/corrective actions. Document methods/metrics. Examples: Multivariate analysis; CluePoints’ SMART™ engine for data inconsistency scoring, outlier detection (adjustable FDR); illustrates via example PDF on mis-calibrated thermometers. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.9 Dealing with Non-Compliance

Formal process: Identify, assess, document failures (protocol/GCP/legislation). Actions: Increase monitoring, senior visits, audits, recruitment holds (as Urgent Safety Measures), retraining. Corrective/preventative actions documented, followed up timely via escalation. Retain for data impact analysis. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.10 Accuracy of Clinical Trial Data

Focus on results reliability, not individual data accuracy. Risk assessment identifies critical data (e.g., endpoints, randomization); high accuracy there, tolerance for others. Trial design mitigates errors (e.g., large randomized trials less affected). Evaluate in risk assessment; initial conservative approach, reduce if concerns unrealized. Prevent errors via design, training, systems. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

2.11 Source Data Verification (SDV)

Focused on critical data (e.g., consent, eligibility, outcomes, safety, non-compliance, IMP accountability) per risk assessment/protocol. Define source data per site. Higher for Type C (exploratory) vs. Type A. Document in protocols/SOPs/strategies; share with investigators for quality improvement. Sampling with escalation if issues. No 100% SDV rationale for inspections; risk-based plans accepted. Discrepancies in non-SDV data expected if unexplained. Electronic data reduces need, emphasize system validation. Remote access (e.g., registries) if consented, confidential (GDPR), authorized. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

3. Responsibilities

• Sponsors: Develop/execute strategies, risk assessments, documentation, oversight of delegates, ensure compliance, retain evidence, adapt as needed, focus on critical areas. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities
• MHRA: Provides guidance; GCP Inspectorate assesses risk-based approaches, accepts central monitoring if justified; no approval required for strategies. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities
• Investigators/Sites: Conduct trials per GCP, retain source documents, submit data/documents, train staff, address queries, consent for data access. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities
• Committees: Oversee conduct, safety, adaptations (TMC/TSC/DMC). https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities
• CROs: Implement delegated functions; assess in strategy. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities

4. Updates

Published 28 January 2022. No future plans for requiring strategy approval by MHRA/REC. Consistent with ICH GCP revisions (e.g., central monitoring not exceptional only). Emphasis on risk-based, proportionate approaches over traditional intensive monitoring. https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities